Artrya (ASX:AYA) Pulls Back After a Major Run as US Salix Rollout Advances

Aditi Sarkar

13 August 2026 02:56 PM AEST

Artrya (ASX:AYA) Pulls Back After a Major Run as US Salix Rollout Advances

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Artrya (ASX:AYA) had gained roughly 247% over one year by 13 August 2026 despite a recent monthly pullback.
The company reported AUD 74.0 million in cash and term deposits at 30 June 2026.
Tanner Health System is live with Salix across five hospitals, with additional US deployments progressing.
Artrya said validation of Salix Coronary Flow was complete, with an FDA submission imminent and clearance targeted for H2 2026.

Artrya (ASX:AYA) has moved from a niche cardiac-AI story to one of the more closely watched small-cap healthcare names on the ASX. The shares had risen roughly 247% over the year to 13 August 2026, but the stock also pulled back around 20% over the preceding month as the market reassessed a valuation built largely on future US commercial growth.

Cash Position Supports the Commercial Rollout

Artrya’s June 2026 quarterly update showed AUD 74.0 million in cash and term deposits at 30 June, including a AUD 30 million six-month deposit. Quarterly operating costs were AUD 6.4 million and net operating cash outflow was about AUD 4.75 million.

Option exercises contributed AUD 2.3 million, reducing the net quarterly cash outflow to roughly AUD 2.6 million. Interest income and an R&D tax rebate also supported the cash position.

US Hospital Deployments Continue

Tanner Health System, Artrya’s first US customer, is live with the Salix platform across five hospitals and is generating subscription and per-scan revenue. Northeast Georgia Health System went live in July 2026, while Cone Health is targeted to go live during the September quarter.

These deployments are important because current customer receipts remain small relative to the company’s market valuation. The pace at which new hospitals convert into recurring Revenue will therefore be a key measure of commercial traction.

Coronary Flow Adds a Regulatory Catalyst

Artrya said validation of its Salix Coronary Flow module had been completed, with an FDA submission imminent and clearance targeted for the second half of 2026. Regulatory clearance would broaden the platform’s commercial opportunity, but timing remains a key dependency.

The company’s valuation is therefore linked not only to hospital deployment but also to successful progression through the US regulatory pathway.

Share Price Volatility Reflects Future Expectations

Artrya traded near AUD 4.61 on 13 August 2026 after reaching levels around AUD 5.77–6.00 in mid-July. The recent pullback followed a large prior re-rating, leaving the stock highly sensitive to commercial milestones, regulatory news and institutional positioning.

An ASX filing on 3 August showed UBS Group AG had ceased to be a substantial holder following late-July trading. Earlier substantial-holder activity also involved Regal Funds Management, Wilson Asset Management and David Paradice.

Revenue Conversion Is the Core Test

Customer receipts for the June quarter were only AUD 0.06 million, underlining the gap between current revenue and the valuation being placed on future growth. That does not alter the progress of the US rollout, but it makes execution especially important.

Upcoming customer go-lives, regulatory milestones and quarterly receipts will help show whether the commercial model is beginning to scale.

What to Watch

Near-term items include the Cone Health go-live, FDA submission and potential clearance for Salix Coronary Flow, preliminary results expected on 19 August 2026, further substantial-holder changes and growth in customer receipts in future quarterly filings.

Risks

Artrya remains pre-profit with minimal current revenue relative to its market capitalisation. FDA timing, hospital procurement cycles and customer conversion can affect the commercial timeline, while the recent share-price swings highlight elevated valuation and momentum risk.

Q1. How much cash did Artrya hold at 30 June 2026?
Artrya reported AUD 74.0 million in cash and term deposits.

Q2. Which US hospital systems are using or preparing to use Salix?
Tanner Health System is live, Northeast Georgia Health System went live in July, and Cone Health is targeted for the September quarter.

Q3. What is the next regulatory milestone?
Artrya is preparing an FDA submission for Salix Coronary Flow, with clearance targeted for the second half of 2026.

Q4. Why is the stock considered high risk despite commercial progress?
Current revenue remains small relative to the company’s valuation, making the share price sensitive to execution, regulatory timing and sentiment.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.